These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 2327180)

  • 41. Modulation of the sodium periodate (NaIO4) response in systemic lupus erythematosus (SLE): effect of interleukin-1 (IL-1), interleukin-2 (IL-2), phorbol myristate acetate (PMA), and indomethacin.
    Phillips R; Lomnitzer R; Rabson AR
    Clin Immunol Immunopathol; 1985 Jan; 34(1):77-83. PubMed ID: 2981169
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer.
    Onodera H; Somers SS; Guillou PJ
    Br J Cancer; 1990 Dec; 62(6):1042-6. PubMed ID: 2257211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Raised immune reactivity of exacerbates lupus erythematosus visceralis. I. Effect of autologous serum on lymphocyte transformation and cytotoxicity].
    Günther W; Diezel W; Meffert H; Sönnichsen N
    Dermatol Monatsschr; 1976 Jan; 162(1):1-8. PubMed ID: 955178
    [No Abstract]   [Full Text] [Related]  

  • 44. Lymphocyte sensitivity assay as a marker for glucocorticoid resistance in lupus: report of two sisters with systemic lupus erythematosus.
    Fajardo-Hermosillo LD; Rodríguez-Navedo Y; Nadal AJ; Vilá LM
    Lupus; 2014; 23(1):88-92. PubMed ID: 24285097
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Depressed natural and lectin-dependent cell-mediated cytotoxicity against adherent HEp-2 cells in patients with systemic lupus erythematosus.
    Perl A; Gonzalez-Cabello R; Láng I; Gergely P
    Immunol Commun; 1982; 11(6):431-40. PubMed ID: 7169224
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polymorphic effects of exogenous gangliosides on antigen-induced lymphoproliferation and generation of MHC unrestricted cell mediated cytotoxicity.
    Spagnoli GC; Ausiello CM; Sconocchia G; Antonelli G; Amici C; Casciani CU
    Int J Immunopharmacol; 1990; 12(7):713-20. PubMed ID: 2292453
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Natural killer funciton in systemic lupus erythematosus.
    Hoffman T
    Arthritis Rheum; 1980 Jan; 23(1):30-5. PubMed ID: 7352941
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of human recombinant interleukin (IL-2) on peripheral blood mononuclear cells of burned patients.
    Jira M; Polacek V; Fara M; Strejcek J; Konigova R
    Burns Incl Therm Inj; 1987 Apr; 13(2):110-3. PubMed ID: 3495321
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of ultraviolet irradiation on natural killer cell function in systemic lupus erythematosus.
    Nived O; Johansson I; Sturfelt G
    Ann Rheum Dis; 1992 Jun; 51(6):726-30. PubMed ID: 1616354
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Natural killer augmentation in systemic lupus erythematosus via a soluble mediator derived from human lymphocytes.
    Kaufman DB
    Arthritis Rheum; 1982 May; 25(5):562-7. PubMed ID: 7082401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Natural killer cell activity in untreated systemic lupus erythematosus.
    Oshimi K; Sumiya M; Gonda N; Kano S; Takaku F
    Ann Rheum Dis; 1982 Aug; 41(4):417-20. PubMed ID: 7114924
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Defective cell mediated immunity in sarcoidosis: effect of interleukin-2.
    Lyons DJ; Gao L; Mitchell EB; Mitchell DN
    Thorax; 1988 Dec; 43(12):992-7. PubMed ID: 3266378
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Natural killer cell activity in systemic lupus erythematosus.
    Oshimi K; Sumiya M; Gonda N; Kano S; Takaku F
    Lancet; 1979 Nov; 2(8150):1023. PubMed ID: 91760
    [No Abstract]   [Full Text] [Related]  

  • 54. The role of cytokines in the immunopathogenesis of lupus.
    Handwerger BS; Rus V; da Silva L; Via CS
    Springer Semin Immunopathol; 1994; 16(2-3):153-80. PubMed ID: 7716703
    [No Abstract]   [Full Text] [Related]  

  • 55. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus.
    Park YW; Kee SJ; Cho YN; Lee EH; Lee HY; Kim EM; Shin MH; Park JJ; Kim TJ; Lee SS; Yoo DH; Kang HS
    Arthritis Rheum; 2009 Jun; 60(6):1753-63. PubMed ID: 19479851
    [TBL] [Abstract][Full Text] [Related]  

  • 58. IL-12 and IL-2 potentiate the in vitro tumor-specific activity of peripheral blood cells from cervical cancer patients.
    Verma V; Sharma V; Shrivastava SK; Nadkarni JJ
    J Exp Clin Cancer Res; 2000 Sep; 19(3):367-74. PubMed ID: 11144531
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interleukin-2 activated cells from peripheral blood of patients with systemic lupus erythematosus.
    Jira M; Strejcek J; Zavadil Z; Antosova E; Rejholec V
    Z Rheumatol; 1990; 49(1):30-3. PubMed ID: 2327180
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.